Clinical Efficacy of Immunoglobulin in Treatment of Sepsis-Associated Thrombocytopenia

HUANG Tianran; SU Muzhen; LV Bo; HE Haiyan

Abstract：Objective To observe the clinical efficacy of immunoglobulin in the treatment of sepsis-associated thrombocytopenia.Methods A total of 65 patients with sepsis-associated thrombocytopenia treated in our hospital from July 2015 to July 2016 were selected and randomly divided into control group (n=32) and observation group (n=33).The control group was given medical treatment,while the observation group was treated with intravenous infusion of immunoglobulin along with the treatment given to the control group.The changes of platelet count,acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ) score of the two groups were detected before the treatment and on the first day,the third day,and the fifth day of the treatment.The incidence of bleeding,28-day mortality,and ICU stay during the treatment of the two groups were also statistically analyzed.Results Since the third day of the treatment,the platelet count in the observation group had been significantly higher than that of the control group,and the APACHE Ⅱ score was remarkably lower than that of the other group,with statistically significant difference (P<0.05).The observation group had lower incidence of bleeding and 28-day mortality and shorter ICU stay during the treatment than the control group with statistically significant difference (P<0.05).Conclusion The use of immunoglobulin in the treatment of sepsis-associated thrombocytopenia can significantly increase the number of platelets,and reduce the risk of bleeding and death of patients,which makes it worth to be promoted.